HOME >> MEDICINE >> NEWS
Phase II study shows combination improves survival of metastatic melanoma patients

CHICAGO -- Two chemotherapy drugs combined with an agent that prevents the growth of blood vessels significantly delayed the spread of tumors in patients with metastatic melanoma, according to study findings presented today at the 2007 American Association of Clinical Oncology (http://www.asco.org/portal/site/ASCO) (ASCO) Annual Meeting.

In this phase II clinical trial of 53 patients, tumor growth was delayed by almost six months, whereas, typically, these cancers begin spreading again eight weeks after chemotherapy treatment, researchers say.

The researchers from Mayo Clinic (http://www.mayo.edu/) and the North Central Cancer Treatment Group (http://ncctg.mayo.edu/) (NCCTG), caution that while the findings are promising, they are preliminary.

"This is the most effective treatment we have ever tested at Mayo Clinic for this type of cancer, but the results need to be validated," says Svetomir Markovic, M.D., Ph.D. (http://mayoresearch.mayo.edu/mayo/research/staff/markovic_sn.cfm), a Mayo Clinic oncologist and the study's principal investigator. "It is important for the public to know there is hope for patients with melanoma."

The study was presented today by Domingo Perez, M.D., the lead author of the study who is a former oncology fellow at Mayo Clinic and is now in private practice in Minneapolis.

"The clinical benefit may seem small, but in the world of melanoma where there is very little progress, this is certainly a strong indication that the combination of chemotherapy with an antiangiogenic agent may be a valid treatment strategy for these patients. But the only way to know this for certain is a head to head comparison with the standard course of treatment," Dr. Perez says.

Melanoma that has metas
'"/>

Contact: Amy Reyes
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
3-Jun-2007


Page: 1 2 3

Related medicine news :

1. GSK announces launch of largest ever Phase III trial in lung cancer treatment
2. MacroChem completes patient enrollment for Phase II trial of EcoNail for treatment of onychomycosis
3. Drug combination proves effective against myeloma in Phase I trial
4. Researchers present Phase 2 clinical results for Acologix AC-100
5. Positive results for ACRUXs lead product in US Phase 3 trial
6. Ebola DNA vaccine produces immune responses in all fully vaccinated volunteers in Phase 1 trial
7. GroPep starts Phase 1 infertility trial
8. Bayer launches Phase III clinical study of Trasylol in elective spinal fusion surgery
9. Joint statement on Savvy Phase 3 trial in Ghana to test the effectiveness of Savvy Gel in preventing HIV
10. NIAID launches first Phase II trial of a global HIV/AIDS vaccine
11. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/19/2019)... (PRWEB) , ... April 19, 2019 , ... ... Doyle, RN/Patient Advocate Manager, The University of Vermont Health Network-CVPH, Plattsburgh, NY with ... to the field of patient advocacy and to fellow patient advocates. Doyle was ...
(Date:4/18/2019)... , ... April 18, 2019 , ... ... on enhancing energy, concentration, memory, relaxation and restful sleep to support a healthy ... formulated to provide mental clarity, focus and vitality. , The portfolio includes a ...
(Date:4/18/2019)... ... April 18, 2019 , ... The Coro Medical official sweepstakes ... Volunteer Fire Department. , As a small, volunteer-only department in rural Mississippi, Livingston ... community and now, is the only department with life-saving equipment of this caliber in ...
(Date:4/17/2019)... , ... April 17, 2019 , ... ... advice. However, recently, this reluctance appears to be changing. Whether because of demographic ... at least, probe their healthcare providers advice. , In the past, efforts to ...
(Date:4/17/2019)... SAN DIEGO (PRWEB) , ... April 17, 2019 ... ... supplement created to help reduce hangover symptoms. This California-made supplement was designed ... productive routines. It is now available for purchase via GotPurpleTree.com and ...
Breaking Medicine News(10 mins):
(Date:4/17/2019)... , ... April 17, 2019 ... ... leading provider of antibodies, kits, and services, today announced that they have ... alignment with organizations that encourage science and environmental education, arts, and support ...
(Date:4/17/2019)... ... April 17, 2019 , ... Kennywood is making ... the autism spectrum, have an amazing experience. As part of this commitment, the ... the International Board of Credentialing and Continuing Education Standards (IBCCES) to organizations who ...
(Date:4/17/2019)... ... ... Women’s Excellence in Obstetrics and Gynecology now offers same day appointments for ... be seen by a provider. We believe in getting patients in right away ... as possible.” Dr. Jonathan Zaidan, MD, FACOG, President of Women’s Excellence. , Women’s Excellence ...
Breaking Medicine Technology:
Cached News: